Preclinical Efficacy of Novel Vesicular Monoamine Transporter 2 Inhibitors as Antagonists of d-Methamphetamine Self-Administration in Rats

A series of studies by Drs. Linda Dwoskin and Michael Bardo demonstrated the preclinical efficacy of novel vesicular monoamine transporter 2 (VMAT2) inhibitors as antagonists of d-methamphetamine self-administration in rats.

[1]  P. Soto,et al.  Preclinical Efficacy of N-Substituted Benztropine Analogs as Antagonists of Methamphetamine Self-Administration in Rats , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[2]  Ashish P. Vartak,et al.  The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse. , 2014, Advances in pharmacology.

[3]  L. Dwoskin,et al.  Oral administration of GZ-793A, a VMAT2 inhibitor, decreases methamphetamine self-administration in rats , 2013, Pharmacology Biochemistry and Behavior.

[4]  L. Dwoskin,et al.  The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats , 2012, Psychopharmacology.

[5]  L. Dwoskin,et al.  Novel N-1,2-Dihydroxypropyl Analogs of Lobelane Inhibit Vesicular Monoamine Transporter-2 Function and Methamphetamine-Evoked Dopamine Release , 2011, Journal of Pharmacology and Experimental Therapeutics.

[6]  L. Dwoskin,et al.  Tetrabenazine inhibition of monoamine uptake and methamphetamine behavioral effects: Locomotor activity, drug discrimination and self-administration , 2011, Neuropharmacology.

[7]  L. Dwoskin,et al.  meso-Transdiene Analogs Inhibit Vesicular Monoamine Transporter-2 Function and Methamphetamine-Evoked Dopamine Release , 2011, Journal of Pharmacology and Experimental Therapeutics.

[8]  Joshua S. Beckmann,et al.  The Novel Pyrrolidine Nor-Lobelane Analog UKCP-110 [cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride] Inhibits VMAT2 Function, Methamphetamine-Evoked Dopamine Release, and Methamphetamine Self-Administration in Rats , 2010, Journal of Pharmacology and Experimental Therapeutics.

[9]  L. Dwoskin,et al.  Lobelane Inhibits Methamphetamine-Evoked Dopamine Release via Inhibition of the Vesicular Monoamine Transporter-2 , 2010, Journal of Pharmacology and Experimental Therapeutics.

[10]  L. Dwoskin,et al.  Lobelane decreases methamphetamine self-administration in rats. , 2007, European journal of pharmacology.

[11]  Allison G. Dempsey,et al.  Interaction of Amphetamines and Related Compounds at the Vesicular Monoamine Transporter , 2006, Journal of Pharmacology and Experimental Therapeutics.

[12]  Abraham Weizman,et al.  The effect of psychostimulants on [3H]dopamine uptake and release in rat brain synaptic vesicles , 2006, Journal of Neural Transmission.

[13]  L. Dwoskin,et al.  Defunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporter. , 2005, Journal of medicinal chemistry.

[14]  J. DaSilva,et al.  In vivo binding of [11C]tetrabenazine to vesicular monoamine transporters in mouse brain. , 1992, Life sciences.

[15]  C. Schuster,et al.  Aminergic influences on intravenous cocaine self-administration by Rhesus monkeys. , 1974, Pharmacology, biochemistry, and behavior.

[16]  C. Schuster,et al.  Cholinergic influence on intravenous cocaine self-administration by rhesus monkeys. , 1973, Pharmacology, biochemistry, and behavior.